Barbara Ryan, Clermont Partners, weighs in on terms of the deal which is expected to close in the second half of 2016. » Read More
David Pyott, Allergan chairman/CEO, discusses the company's earnings, and products in the big pharma pipeline, with Mad Money's Jim Cramer.
Mad Money host Jim Cramer explains why Allergan isn't about to fall off a patent cliff like so many other big pharma companies. David Pyott, Allergan chairman, president & CEO weighs in on the company's earnings.
Making a case for lap-band surgery and discussing the benefits to patients and insurance companies, with David Pyott, Allergan CEO.
David Pyott, Allergan chairman & CEO, discusses earnings and the aesthetics business, including Botox.